TargED Biopharmaceuticals raises EUR 39 Million in Series A

- Financing with equal contribution by an international investor syndicate comprising of Andera Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures - Funds

Related Keywords

Norway , Germany , Munich , Bayern , Paris , France General , France , Stockholm , Sweden , Utrecht , Netherlands , United Kingdom , Belgium , Oslo , Austria , Velden , Amsterdam , Noord Holland , Belgian , German , Olivier Litzka , Thrombocytopenia Purpura , Andera Croissance , Thijs Cohen Tervaert , Jacob Lange Moresco , Roger Franklin , Kristof Vercruysse , Coen Maas , Marc Van Moorsel , Andera Life Sciences , University Medical Center Utrecht , Utrecht Health Seed Fund , European Life Sciences , Life Sciences , Department Of Clinical Chemistry , Andera Partners , Hadean Ventures , Inkef Capital , Sunstone Life Science , Sunstone Life Science Ventures , Biogeneration Ventures , Curie Capital , Utrecht Health Seed , Thrombotic Thrombocytopenia Purpura , Acute Ischemic Stroke , Chief Executive Officer , Jan Van , Cohen Tervaert , Associate Professor Coen Maas , Managing Partner , Targeted Enzyme , Associate Professor , Clinical Chemistry , Steven De Maat , Thrombotic Thrombocytopenic Purpura , Andera Midcap , Andera Expansion , Andera Acto , Andera Infra , Onward Medical , Targed , Biopharmaceuticals , Raises , Billion , Series , Financing , Ring , Roundbreaking , Thrombolytic , Treatment , Patients ,